MX2022013867A - Combinacion farmaceutica que comprende tno155 y nazartinib. - Google Patents

Combinacion farmaceutica que comprende tno155 y nazartinib.

Info

Publication number
MX2022013867A
MX2022013867A MX2022013867A MX2022013867A MX2022013867A MX 2022013867 A MX2022013867 A MX 2022013867A MX 2022013867 A MX2022013867 A MX 2022013867A MX 2022013867 A MX2022013867 A MX 2022013867A MX 2022013867 A MX2022013867 A MX 2022013867A
Authority
MX
Mexico
Prior art keywords
tno155
nazartinib
pharmaceutical combination
treatment
compositions
Prior art date
Application number
MX2022013867A
Other languages
English (en)
Spanish (es)
Inventor
Huaixiang Hao
Chen Liu
Susan E Moody
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2022013867A publication Critical patent/MX2022013867A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022013867A 2020-05-08 2021-05-06 Combinacion farmaceutica que comprende tno155 y nazartinib. MX2022013867A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063021772P 2020-05-08 2020-05-08
US202063117388P 2020-11-23 2020-11-23
PCT/IB2021/053867 WO2021224867A1 (en) 2020-05-08 2021-05-06 Pharmaceutical combination comprising tno155 and nazartinib

Publications (1)

Publication Number Publication Date
MX2022013867A true MX2022013867A (es) 2022-11-30

Family

ID=75904981

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013867A MX2022013867A (es) 2020-05-08 2021-05-06 Combinacion farmaceutica que comprende tno155 y nazartinib.

Country Status (12)

Country Link
US (1) US20230172928A1 (cg-RX-API-DMAC7.html)
EP (1) EP4146217A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023524789A (cg-RX-API-DMAC7.html)
KR (1) KR20230008719A (cg-RX-API-DMAC7.html)
CN (1) CN115397421A (cg-RX-API-DMAC7.html)
AU (1) AU2021267213B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022022305A2 (cg-RX-API-DMAC7.html)
CA (1) CA3179994A1 (cg-RX-API-DMAC7.html)
IL (1) IL297043A (cg-RX-API-DMAC7.html)
MX (1) MX2022013867A (cg-RX-API-DMAC7.html)
TW (1) TW202207933A (cg-RX-API-DMAC7.html)
WO (1) WO2021224867A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL304526B2 (en) 2018-09-29 2025-05-01 Novartis Ag Production of compounds and preparations for inhibiting the activity of SHP2
EP3856345A1 (en) 2018-09-29 2021-08-04 Novartis AG Process of manufacture of a compound for inhibiting the activity of shp2
ES3040751T3 (en) 2020-07-08 2025-11-04 Novartis Ag Manufacture of compounds and compositions for inhibiting the activity of shp2
AU2022341107A1 (en) 2021-09-08 2024-02-29 Amgen Inc. Sotorasib and an egfr antibody for treating cancer comprising a kras g12c mutation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CN110730678B (zh) * 2017-01-10 2022-07-15 诺华股份有限公司 包含alk抑制剂和shp2抑制剂的药物组合
EP3856345A1 (en) * 2018-09-29 2021-08-04 Novartis AG Process of manufacture of a compound for inhibiting the activity of shp2

Also Published As

Publication number Publication date
IL297043A (en) 2022-12-01
AU2021267213B2 (en) 2023-11-30
TW202207933A (zh) 2022-03-01
JP2023524789A (ja) 2023-06-13
AU2021267213A1 (en) 2022-11-03
CN115397421A (zh) 2022-11-25
WO2021224867A1 (en) 2021-11-11
US20230172928A1 (en) 2023-06-08
KR20230008719A (ko) 2023-01-16
BR112022022305A2 (pt) 2022-12-20
EP4146217A1 (en) 2023-03-15
CA3179994A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
EP4249000A3 (en) Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
MX2021009563A (es) Combinacion farmaceutica que comprende tno155 y ribociclib.
MX2021009562A (es) Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1.
MX2024009727A (es) Terapias de combinacion.
PH12019502132A1 (en) Combination therapy for the treatment or prevention of tumours
EA202190749A1 (ru) Способы комбинированной терапии
EP4674415A3 (en) Azaquinolines as inhibitors of cd38
MX2022012471A (es) Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas.
MX2024008115A (es) Tratamiento conjunto para tratamiento contra el cancer.
MX2025003908A (es) Compuesto inhibidor de parg
MX2024004213A (es) Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados.
BR112022022305A2 (pt) Combinação farmacêutica que compreende tno155 e nazartinibe
WO2024006292A3 (en) Methods of treating cancer
PH12021552588A1 (en) Cd73 inhibitors
WO2022020353A3 (en) Methods and compositions for treatment and prevention of coronavirus infection
WO2021158635A8 (en) Anti-viral compositions and methods of use
MX2025012183A (es) Formas cristalinas de un inhibidor de ras
ZA202108579B (en) Inhibitors of notch signalling pathway and use thereof in treatment of cancers
MX2022015552A (es) Prevencion, reduccion o mejora del olor a persona mayor.
MX2024000238A (es) Derivados de pirrolopiridona utiles en el tratamiento del cancer.
MX2020010231A (es) Una combinacion farmaceutica triple que comprende dabrafenib, trametinib y un inhibidor de erk.
MX2025011417A (es) Programa de dosificacion de un inhibidor de her.2
MX2025011153A (es) Polipeptidos cas con reconocimiento de pam alterado
MX2023005501A (es) Combinaciones de inhibidores de metap2 e inhibidores de cdk4/6 para el tratamiento de cáncer.
MX2025003004A (es) Formas farmaceuticas de un inhibidor de cd73